Smad phosphoisoform signaling specificity: The right place at the right time

Carcinogenesis

Volumn 32, Issue 11, 2011, Pages 1578-1588

  Matsuzaki, Koichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CANCER INHIBITION; CARCINOGENESIS; CARCINOMA IN SITU; ENZYME ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 80755187843     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr172     Document Type: Review

References (126)

1. Moses,H.L. et al. (1990) TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 63, 245-247.
2. Roberts,A.B. et al. (1990) The transforming growth factor-βs. In Sporn,M.B. and Roberts,A.B. (eds.) Peptide Growth Factors and Their Receptors. Springer, Berlin, Germany, pp. 419-472.
3. Bellam,N. et al. (2010) TGF-β signaling alterations and colon cancer. Cancer Treat. Res., 155, 85-103.
4. Markowitz,S. et al. (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-1338.
5. Moustakas,A. et al. (2005) Non-Smad TGF-β signals. J. Cell Sci., 118, 3573-3584.
6. Fearon,E.R. et al. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
7. Hahn,W.C. et al. (2002) Rules for making human tumor cells. N. Engl. J. Med., 347, 1593-1603.
8. Loeb,L.A. et al. (2003) Multiple mutations and cancer. Proc. Natl Acad. Sci. USA, 100, 776-781.
9. Futreal,P.A. et al. (2004) A census of human cancer genes. Nat. Rev. Cancer, 4, 177-183.
10. Kalluri,R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
11. Thiery,J.P. et al. (2009) Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890.
12. de Caestecker,M.P. et al. (2000) Role of transforming growth factor-β signaling in cancer. J. Natl Cancer Inst., 92, 1388-1402.
13. Roberts,A.B. et al. (2006) Smad3 is key to TGF-β-mediated epithelial--to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev., 17, 19-27.
14. Saunier,E.F. et al. (2006) TGF-β inhibition for cancer therapy. Curr. Cancer Drug Targets, 6, 565-578.
15. Heldin,C.H. et al. (1997) TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471.
16. Massagué,J. (1998) TGF-β signal transduction. Annu. Rev. Biochem., 67, 753-791.
17. Wrana,J.L. (2000) Regulation of Smad activity. Cell, 100, 189-192.
18. Datto,M. et al. (2000) The Smads: transcriptional regulation and mouse models. Cytokine Growth Factor Rev., 11, 37-48.
19. Derynck,R. et al. (2008) The TGF-β family. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
20. Kretzschmar,M. et al. (1999) A mechanism of repression of TGF-β/Smad signaling by oncogenic Ras. Genes Dev., 13, 804-816.
21. Mori,S. et al. (2004) TGF-β and HGF transmit the signals through JNKdependent Smad2/3 phosphorylation at the linker regions. Oncogene, 23, 7416-7429.
22. Matsuura,I. et al. (2004) Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature, 430, 226-231.
23. Kamaraju,A.K. et al. (2005) Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-β-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem., 280, 1024-1036.
24. Sekimoto,G. et al. (2007) Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res., 67, 5090-5096.
25. Matsuzaki,K. et al. (2009) Smad2 and Smad3 phosphorylated at both linker and COOH-terminal regions transmit malignant TGF-β signal in later stages of human colorectal cancer. Cancer Res., 69, 5321-5330.
26. Liu,F. (2006) Smad3 phosphorylation by cyclin-dependent kinases. Cytokine Growth Factor Rev., 17, 9-17.
27. Ikushima,H. et al. (2011) TGF-βsignal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β. Cell Tissue Res., in press.
28. ten Dijke,P. et al. (2004) New insights into TGF-β-Smad signaling. Trends Bio. Sci., 29, 265-273.
29. Yagi,K. et al. (1999) Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem., 274, 703-709.
30. Chang,L. et al. (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
31. Derynck,R. et al. (2003) Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature, 425, 577-584.
32. Shaulian,E. et al. (2002) AP-1 as a regulator of cell life and death. Nat. Cell Biol., 4, E131-E136.
33. Zhang,Y.E. (2009) Non-Smad pathways in TGF-β signaling. Cell Res., 19, 128-139.
34. Wicks,S.J. et al. (2000) Inactivation of Smad-transforming growth factor b signaling by Ca(+)-calmodulin-dependent protein kinase II. Mol. Cell. Biol., 20, 8103-8111.
35. Furukawa,F. et al. (2003) p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology, 38, 879-889.
36. Ho,J. et al. (2005) The G protein-coupled receptor kinase-2 is a TGF-β--inducible antagonist of TGF-β signal transduction. EMBO J., 24, 3247-3258.
37. Millet,C. et al. (2009) A negative feedback control of transforming growth factor-β signaling by glycogen synthase kinase 3-mediated Smad3 linker phosphorylation at Ser-204. J. Biol. Chem., 284, 19808-19816.
38. Alarcón,C. et al. (2009) Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell, 139, 757-769.
39. Matsuzaki,K. (2006) Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis. Histol. Histopathol., 21, 645-662
40. Zhu,H. et al. (1999) A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature, 400, 687-693.
41. Lin,X. et al. (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasomedependent degradation of Smad2 in transforming growth factor-β signaling. J. Biol. Chem., 275, 36818-36822.
42. Zhang,Y. et al. (2001) Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl Acad. Sci. USA, 98, 974-979.
43. Gao,S. et al. (2009) Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-β signaling. Mol. Cell, 36, 457-468.
44. Sapkota,G. et al. (2006) Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small COOH-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-β pathways. J. Biol. Chem., 281, 40412-40419.
45. Wrighton,K.H. et al. (2009) Phospho-control of TGF-β superfamily signaling. Cell Res., 19, 8-20.
46. Yamagata,H. et al. (2005) Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res., 65, 157-165.
47. Yoshida,K. et al. (2005) Transforming growth factor-β and plateletderived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am. J. Pathol., 166, 1029-1039.
48. Matsuzaki,K. et al. (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology, 46, 48-57.
49. Murata,M. et al. (2009) Hepatitis B virus X protein shifts human hepatic TGF-β signaling from tumor-suppression to oncogenesis in early chronic hepatitis B. Hepatology, 49, 1203-1217.
50. Nagata,H. et al. (2009) Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. Hepatology, 49, 1944-1953.
51. Kawamata,S. et al. (2011) Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis. Inflamm. Bowel Dis., 17, 683-695.
52. Frederick,J.P. et al. (2004) Transforming growth factor β-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol. Cell. Biol., 24, 2546-2559.
53. Datto,M.B. et al. (1995) Transforming growth factor β induces the cyclindependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA, 92, 5545-5549.
54. Hannon,G.J. et al. (1994) p15INK4B is a potential effector of TGF-βinduced cell cycle arrest. Nature, 371, 257-261.
55. Polyak,K. et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8, 9-22.
56. Sherr,C.J. et al. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13, 1501-1512.
57. Yang,Y.A. et al. (2006) Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell, 9, 445-457.
58. de Caestecker,M.P. et al. (1998) Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev., 12, 1587-1592.
59. Lehmann,K. et al. (2000) Raf induces TGF-β production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev., 14, 2610-2622.
60. Yue,J. et al. (2000) Requirement of Ras/MAPK pathway activation by transforming growth factor β for transforming growth factor β1 production in a Smad-dependent pathway. J. Biol. Chem., 275, 30765-30773.
61. Oft,M. et al. (2002) Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol., 4, 487-494.
62. Funaba,M. et al. (2002) Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J. Biol. Chem., 277, 41361-41368.
63. Janda,E. et al. (2002) Ras and TGF-β cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol., 156, 299-313.
64. Suzuki,K. et al. (2007) Transforming growth factor b signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res., 67, 3673-3682.
65. Burch,M.L. et al. (2010) TGF-β stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell. Mol. Life Sci., 67, 2077-20790.
66. Jiang,W. et al. (2010) Role of cross-talk between the Smad2 and MAPK pathways in TGF-β1-induced collagen IV expression in mesangial cells. Int. J. Mol. Med., 26, 571-576.
67. Wang,G. et al. (2005) The Smad3 linker region contains a transcriptional activation domain. Biochem. J., 386, 29-34.
68. Prokova,V. et al. (2005) Characterization of a novel transcriptionally active domain in the transforming growth factor b-regulated Smad3 protein. Nucleic Acids Res., 33, 3708-3721.
69. Vasilaki,E. et al. (2009) Novel regulation of Smad3 oligomerization and DNA binding by its linker domain. Biochemistry, 48, 8366-8378.
70. Wakefield,L.M. et al. (2002) TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev., 12, 22-29.
71. Soucek,L. et al. (2010) The ups and downs of Myc biology. Curr. Opin. Genet. Dev., 20, 91-95.
72. Claassen,G.F. et al. (2000) A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor b-induced cell-cycle arrest. Proc. Natl Acad. Sci. USA, 97, 9498-9503.
73. Feng,X.-H. et al. (2002) Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-β-mediated induction of the CDK inhibitor p15Ink4B. Mol. Cell, 9, 133-143.
74. Moustakas,A. et al. (1998) Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl Acad. Sci. USA, 95, 6733-6738.
75. Pardali,K. et al. (2007) Actions of TGF-β as tumor suppressor and prometastatic factor in human cancer. Biochim. Biophys. Acta, 1775, 21-62.
76. Feng,X.-H. et al. (2000) Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15Ink4B transcription in response to TGF-β. EMBO J., 19, 5178-5193.
77. Seoane,J. et al. (2001) TGF-β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol., 3, 400-408.
78. Seoane,J. et al. (2002) Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature, 419, 729-734.
79. Weinberg,R.A. (2007) The Biology of Cancer. Garlang Science, New York, NY.
80. Jones,P.A. et al. (2007) The epigenomics of cancer. Cell, 128, 683-692.
81. Hengst,L. et al. (1996) Translational control of p27Kip1 accumulation during the cell cycle. Science, 271, 1861-1864.
82. Reynisdottir,I. et al. (1997) The subcellular locations of p15Ink4b and p27Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev., 11, 492-503.
83. Chu,I.M. et al. (2007) p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell, 128, 281-294.
84. Grimmler,M. et al. (2007) Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell, 128, 269-280.
85. Serres,M.P. et al. (2011) Cytoplasmic p.27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene, 30, 2846-2858.
86. Chu,I.M. et al. (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer, 8, 253-267
87. Oft,M. et al. (1996) TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev., 10, 2462-2477.
88. Guo,X. et al. (2009) Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res., 19, 71-88.
89. Kessenbrock,K. et al. (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141, 52-67.
90. Stuelten,C.H. et al. (2005) Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-a and TGF-β. J. Cell Sci., 118, 2143-2153.
91. Wang,G. et al. (2009) Transforming growth factor-β-inducible phosphorylation of Smad3. J. Biol. Chem., 284, 9663-9673.
92. Matsuura,I. et al. (2010) Pin1 promotes transforming growth factor-βinduced migration and invasion. J. Biol. Chem., 285, 1754-1764.
93. Yeh,E.S. et al. (2007) PIN1, the cell cycle and cancer. Nat. Rev. Cancer, 7, 381-388.
94. Nakano,A. et al. (2009) Pin1 down-regulates transforming growth factorb (TGF-β) signaling by inducing degradation of Smad proteins. J. Biol. Chem., 284, 6109-6115.
95. Saika,S. et al. (2004) Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am. J. Pathol., 164, 651-663.
96. Horiguchi,K. et al. (2009) Role of Ras signaling in the induction of snail by transforming growth factor-β. J. Biol. Chem., 284, 245-253.
97. Green,D.R. et al. (2002) A matter of life and death. Cancer Cell, 1, 19-30.
98. Zhu,L. et al. (2001) Coordinating cell proliferation and differentiation. Curr. Opin. Genet. Dev., 11, 91-97.
99. Hague,A. et al. (1993) Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int. J. Cancer, 55, 498-505.
100. Maltzman,T. et al. (2001) K-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology, 121, 302-309.
101. Glick,A.B. et al. (1996) Transforming growth factor β1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res., 56, 3645-3650.
102. Tremain,R. et al. (2000) Defects in TGF-β signaling overcome senescence of mouse keratinocytes expressing v-Ha-ras. Oncogene, 19, 1698-1709.
103. Yang,H. et al. (2001) Autocrine transforming growth factor b suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells. Cell Growth Differ., 12, 119-127.
104. Derijard,B. et al. (1994) JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 76, 1025-1037.
105. Malumbres,M. et al. (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153-166.
106. Engel,M.E. et al. (1999) Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription. J. Biol. Chem., 274, 37413-37420.
107. Grimm,O.H. et al. (2002) Nuclear exclusion of Smad2 is a mechanism leading to loss of compete. Nat. Cell Biol., 4, 519-522.
108. Javelaud,D. et al. (2005) Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGFb: implications for carcinogenesis. Oncogene, 24, 5742-5750.
109. Arany,P.R. et al. (2008) Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition. Oncogene, 27, 2507-2512.
110. Hamajima,H. et al. (2009) Modulation of the transforming growth factorb1-induced Smad phosphorylation by the extracellular matrix receptor beta1-integrin. Int. J. Oncol., 35, 1441-1447.
111. Lin,Q. et al. (2010) SKI promotes Smad3 linker phosphorylations associated with the tumor-promoting trait of TGF-β. Cell Cycle, 9, 1684-1689.
112. Hong,H.Y. et al. (2010) 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-β 1. Mol. Cells, 29, 305-309.
113. Brown,J.D. et al. (1999) MEKK-1, a component of the stress (stressactivated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J. Biol. Chem., 274, 8797-8805.
114. Hayashida,T. et al. (2003) Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-β-dependent responses in human mesangial cells. FASEB J., 17, 1576-1578.
115. Yang,Y. et al. (2008) Compound Astragalus and Salvia miltiorrhiza extract exerts anti-fibrosis by mediating TGF-β/Smad signaling in myofibroblasts. J. Ethnopharmacol., 118, 264-270.
116. He,S. et al. (2010) Mechanisms of transforming growth factor b(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br. J. Dermatol., 162, 538-546.
117. Sasseville,M. et al. (2010) Growth differentiation factor 9 signaling requires ERK1/2 activity in mouse granulosa and cumulus cells. J. Cell Sci., 123, 3166-3176.
118. Rachakonda,G. et al. (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene, 29, 3703-3714.
119. Velden,J.L. et al. (2011) c-Jun N-Terminal Kinase 1 promotes TGF-β1-induced epithelial to mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. Am. J. Respir. Cell Mol. Biol, 44, 571-581.
120. Wrighton,K.H. et al. (2006) Small C-terminal domain phosphatases dephosphorylate the regulatory linker regions of Smad2 and Smad3 to enhance transforming growth factor-β signaling. J. Biol. Chem., 281, 38365-38375.
121. Chen,C.J. et al. (2006) REVEAL-HBV study group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295, 65-73.
122. Sawyers,C.L. (2008) The cancer biomarker problem. Nature, 452, 548-552
123. Thorgeirsson,S.S. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 31, 339-346.
124. Felsher,D.W. (2004) Reversibility of oncogene-induced cancer. Curr. Opin. Genet. Dev., 14, 37-42.
125. Heldin,C.H. et al. (2011) Role of Smads in TGF-β signaling. Cell Tissue Res. In press.
126. Ashcroft,G.S. et al. (1999) Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat. Cell Biol., 1, 260-266.